Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Completed · Phase 2

Conditions studied: Psoriasis

In brief

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .

Key facts

Study ID

NCT02933528

Run by

Sun Pharmaceutical Industries, Inc.

People needed

24

Starts

2016-07-11

Expected to finish

2017-11-27

Last updated by the study team

2018-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non-pregnant, non-lactating females 18 years of age or older.
• IRE-approved, signed informed consent form that meets all criteria of current FDA regulations.

You may not qualify if…

• Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.

Where it is running

• Taro Pharmaceuticals USA, Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.